Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reparixin for Cancer Related Fatigue in Breast Cancer
NCT05212701Phase 2Withdrawn
- Sponsor
- Dompé
- Start
- Apr 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of reparixin in cancer-related fatigue (CRF), sponsored by Dompé. Planned start Apr 2022; status: withdrawn.
02
Drugs
reparixin
03
Conditions
cancer-related fatigue (CRF)
Beyond the preview
Go deeper on NCT05212701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05212701.